CD40LG CD40 ligand
ENSG00000102245 · protein coding · Open Targets profile
Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed:1280226, PubMed:31331973). Costimulates T-cell proliferation and cytokine production (PubMed:8617933). Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:8617933). Induces the activation of NF-kappa-B (PubMed:15067037, PubMed:31331973). Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:15067037). Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:15067037). Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity). Involved in immunoglobulin class switching (By similarity). {ECO:0000250|UniProtKB:P27548, ECO:0000269|PubMed:1280226, ECO:0000269|PubMed:15067037, ECO:0000269|PubMed:31331973, ECO:0000269|PubMed:8617933}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Pocket
- Antibody
- Advanced Clinical, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.05808600038290024 (upper bound 0.2755500078201294). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 17 registry trials, updated in the last three years, of the most advanced drugs against CD40LG (dazodalibep, dapirolizumab pegol, ravagalimab, tegoprubart, ruplizumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- UCB Cares001 844 599 2273 (UCB) · 3 of 3 trials Phase 2+Ph3NCT06617325 · A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosusbrief
- Piotr WitkowskiUniversity of Chicago · 1 of 1 trials Phase 2+
Registry trials of dazodalibep, dapirolizumab pegol, ravagalimab, tegoprubart, ruplizumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 4 of 16 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
1 trials of drugs against CD40LG were stopped early
Terminated, withdrawn and suspended interventional trials of dazodalibep, dapirolizumab pegol, ravagalimab, tegoprubart, ruplizumab, toralizumab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 1 most recent of 1.
- withdrawn · 2022-02-01 · AbbVie · Ravagalimab“Study canceled”
Paediatric incentives and obligations for CD40LG's drugs
For dazodalibep, dapirolizumab pegol, ravagalimab, tegoprubart, ruplizumab, toralizumab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · CD40LG is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000232482 (tegoprubart, Prevention of rejection of transplanted kidney): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 11 Jul 2025; EMEA-002617-PIP01-19 (ravagalimab, Treatment of ulcerative colitis): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 25 Jun 2020; EMEA-002702-PIP01-19 (Dapirolizumab pegol, Treatment of Systemic Lupus Erythematosus (SLE)): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 1 Dec 2020; EMEA-002617-PIP02-19 (ravagalimab, Treatment of Sjögren's syndrome): W: decision granting a waiver in all age groups for all conditions or indications, 15 Jul 2020Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names dazodalibep, dapirolizumab pegol, ravagalimab, tegoprubart, ruplizumab, toralizumabRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of dazodalibep, dapirolizumab pegol, ravagalimab, tegoprubart, ruplizumab, toralizumabRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of dazodalibep, dapirolizumab pegol, ravagalimab, tegoprubart, ruplizumab, toralizumabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 5 interventional studies of dazodalibep, dapirolizumab pegol, ravagalimab, tegoprubart, ruplizumab, toralizumab include patients under 18; 2 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 6 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.